For the quarter ending 2026-03-31, ALMR has $186,451K in assets. $129,526K in debts. $64,586K in cash and cash equivalents.
| Balance Sheets | 2026-03-31 | |||
|---|---|---|---|---|
| Cash and cash equivalents | 64,586 | |||
| Accounts receivable | 19,524 | |||
| Inventory | 39,931 | |||
| Prepaid expenses and other current assets | 17,432 | |||
| Total current assets | 141,473 | |||
| Restricted cash | 4,907 | |||
| Property and equipment, net | 10,472 | |||
| Operating lease right-of-use assets | 25,671 | |||
| Capitalized software, net | 1,836 | |||
| Other assets - noncurrent | 2,092 | |||
| Total assets | 186,451 | |||
| Accounts payable | 5,635 | |||
| Accrued and other current liabilities | 16,814 | |||
| Short-term operating lease liabilities | 1,599 | |||
| Total current liabilities | 24,048 | |||
| Long-term operating lease liabilities | 28,979 | |||
| Warrant liabilities | 331 | |||
| Term debt | 9,877 | |||
| Convertible note | 65,094 | |||
| Other noncurrent liabilities | 1,197 | |||
| Total liabilities | 129,526 | |||
| Convertible preferred stock | 234,996 | |||
| Common stock | 1 | |||
| Additional paid-in capital | 12,108 | |||
| Accumulated other comprehensive loss | -80 | |||
| Accumulated deficit | -190,100 | |||
| Total stockholders' deficit | -178,071 | |||
| Total liabilities, convertible preferred stock and stockholders' deficit | 186,451 | |||
Alamar Biosciences, Inc. (ALMR)
Alamar Biosciences, Inc. (ALMR)